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Acute Myocardial Infarction (AMI) is the leading cause of death and 
disability in industrialized countries and is expected to become so in 
emerging countries by 2020. AMI is one of the main diseases with the 
highest rate of misdiagnosis. Of the majority of patients that arrive to the 
Emergency Department (ED) with cardiac pain and other symptoms 
suggestive of myocardial infarction, only a small portion actually may 
experience an Acute Myocardial Infarction. Therefore, diagnosing Acute 
Myocardial Infarction within such a large proportion of patients with 
cardiac pain is indeed a diagnostic challenge.  
For the correct diagnosis, it is essential to collect blood samples from the 
patient for the measurement of cardiac biomarkers, namely cardiac 
troponin I and cardiac troponin T.  
In this thesis, it is proposed a new type of biosensor for the early and 
reliable diagnosis of Acute Myocardial Infarction based on the use of 
metallic nanoparticles attached with aptamers as new Surface Enhanced 
Raman Scattering (SERS) platforms for the specific detection of cardiac 
troponin-I. Firstly, gold and silver colloidal nanoparticles (NPs) were 
synthesized via the classical citrate reduction method and later 
characterized to assess the quality of the substrate. Larger gold 
nanoparticles (AuNPs) with sizes ranging from 35-96 nm were also 
prepared by a seed-mediated growth method. The detection of cardiac 
troponin I proceeded with the addition of the protein at lower 
concentrations to the metallic colloids. The final results showed that 
AuNPs with larger sizes are good candidates to be used as SERS 
platforms for the detection of cardiac troponin I, because they have 
presented the highest enhancement of the Raman signals of the protein. 
These experiments have shown that larger AuNPs are definitely most 
suitable for this kind of applications. Peak bands were found to be 
attributed from characteristic bands present in proteins.  
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Enfarte Agudo do Miocárdio, troponina cardíaca-I, biossensores, 
aptâmeros, SERS, nanopartículas metálicas 
 
 
O Enfarte Agudo do Miocárdio é a principal causa de morte e de 
incapacidade nos países desenvolvidos e prevê-se que seja também nos 
países em desenvolvimento até 2020. O Enfarte Agudo do Miocárdio é 
uma das principais patologias com a maior taxa de erro no diagnóstico. 
Entre a maioria de pacientes que se apresenta com dor torácica ou outro 
sintoma sugestivo de Enfarte Agudo do Miocárdio, apenas uma pequena 
porção de pacientes realmente manifesta a patologia. Deste modo, 
diagnosticar um Enfarte Agudo do Miocárdio numa larga proporção de 
pacientes com dor torácica é de facto um desafio para os clínicos.  
Para o correto diagnóstico é essencial que se colete uma amostra de 
sangue do paciente para a medição de biomarcadores cardíacos 
sobretudo as troponinas cardíacas I e T.   
Nesta tese propõe-se um novo tipo de biossensor para o diagnóstico 
precoce e fiável de Enfarte Agudo do Miocárdio que se baseia na 
funcionalização de aptâmeros à superfície de nanopartículas metálicas 
como novas plataformas de SERS (Surface Enhanced Raman 
Scattering) para a deteção específica da troponina cardíaca I. Numa 
primeira fase, nanopartículas de ouro e de prata foram sintetizadas pela 
via clássica de redução com citrato e subsequentemente caracterizadas 
para determinar a qualidade dos substratos obtidos.  
Nanopartículas com tamanhos que rondam os 35-96 nm foram 
igualmente sintetizadas pelo processo de crescimento mediado por 
sementes. A deteção da troponina cardíaca I passou pela adição de 
baixas concentrações de proteína aos coloides metálicos. Os resultados 
finais demonstraram que as nanopartículas de ouro com tamanhos 
superiores aparentam ser bons candidatos a substratos para SERS para 
a deteção da troponina cardíaca-I, uma vez que apresentaram melhor 
intensificação de sinais de Raman da proteína. Estes testes permitiram 
concluir que as nanopartículas de ouro de maiores dimensões são de 
facto mais adequadas para este tipo de aplicações. Os picos obtidos 
podem ser atribuídos a bandas características encontradas nas 
proteínas.  
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1. Introduction 
 
1.1. Structure of the thesis   
 
This thesis is divided into five main chapters. The first chapter makes the bridge 
between problem-need-solution. In this chapter, the pathophysiology of Acute Myocardial 
Infarction and the way it is diagnosed in the clinical practice are reviewed in order to provide 
a better understanding of the real problem. After needs identification, it is presented a 
description of the proposed biosensor as an innovative solution for the early and reliable 
diagnosis of Acute Myocardial Infarction.  
The second chapter is objectively targeted to the experimental synthesis and 
characterization of metallic nanoparticles, namely gold and silver, the chosen materials that 
will form the biosensor. 
The third chapter presents the results of the detection of cardiac troponin I obtained 
by SERS analysis as a role model for the envisaged biosensor.  
The fourth chapter summarizes the main conclusions of the attained results and 
states improvements and suggestions that will be implemented to the biosensor in the near 
future.  
The fifth chapter is focused on the experimental procedures and instrumentation that 
were relevant to the proposed work. In this chapter, there is room for more experimental 
details, including a description of the functional principles of the employed instrumentation.  
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1.2. Overview of Acute Myocardial Infarction  
 
Cardiovascular disease (CVD) is currently the leading cause of death and disability 
in industrialized countries and is expected to become so in emerging countries by 2020 [1, 
2]. More than 17 million people died from CVDs in 2008. About 7.2 million of these deaths 
are due to coronary artery disease (CAD), also known as ischemic heart disease [1, 3-5]. 
Ischemic heart disease is a multi-factorial condition, resulting from the convergence 
of genetics, environment, diet and lifestyle. Recognized risk factors for the development of 
ischemic heart disease include family history, high blood pressure, smoking, elevated low-
density lipoprotein (LDL cholesterol) diabetes, physical inactivity, and obesity. One of the 
main underlying pathological processes of ischemic heart disease is known as 
atherosclerosis [3, 6]. Atherosclerosis is an inflammatory process affecting medium and 
large sized blood vessels throughout the cardiovascular system. The process begins when 
LDL cholesterol, white blood cells and hemodynamic forces are combined specially at sites 
of disturbed laminar flow, namely where the arteries branch, leading to the formation of an 
atherosclerotic plaque. The formation of the atherosclerotic plaque is responsible for the 
narrowing of the arteries, compromising seriously the blood supply to the highly active 
cardiac muscle, the myocardium [6-9]. 
Plaque disruption is considered to occur as a result of the physical shear forces 
acting on it from inside the lumen or secondary to inflammatory and degradation processes 
within the plaque. In either case, the acute plaque disruption leads to a complex interaction 
between lipids, white blood cells and smooth-muscle cells exposed from the lipid core to 
the circulation, triggering the formation of a blood clot (thrombus) [10, 11].The blood clot 
may occlude the coronary blood vessels and interrupt coronary blood flow, resulting in 
Acute Myocardial Infarction (AMI). AMI compromises the blood supply to the myocardium, 
deprives the heart of oxygen and nutrients (ischemia) and leads to significant cardiac tissue 
destruction (cell death or necrosis) (Figure 1) [11-13]. 
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Figure 1. The underlying mechanisms of AMI [13]. 
 
The pathology is also characterized by a high rate of misdiagnosis since some true 
AMI patients are inappropriately discharged from hospitals, leading to an increase in the 
morbidity and mortality rates, while other non-AMI patients are unnecessary admitted to 
hospitals [14]. Approximately 15-20 million patients per year in the United States and 
Europe arrive to the Emergency Department (ED) with chest pain or other symptoms 
suggestive of AMI. However, it is known that only 10-15% of the patients with chest pain 
actually have myocardial infarction [15, 16]. 
Therefore, differentiating patients with symptoms suggestive of AMI within the very 
large proportion of patients with suspected cardiac pain is a diagnostic challenge, mainly in 
patients without clear symptoms or electrocardiographic features [1]. Since the majority of 
patients presenting with acute chest pain do not have acute ischemia, the rapid identification 
of these patients would substantially reduce both overcrowding of emergency departments 
and the costs with prolonged stays and unnecessary hospital admissions, estimated in 
billions of euros annually [16, 17]. Thus, an early and reliable diagnosis is extremely 
important, not only in saving lives but also in saving a great deal of time and costs in patient 
related care [14]. 
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1.3. Pathophysiology of Acute Coronary Syndromes  
 
The vast array of clinical symptoms manifested after coronary plaque disruption are 
often referred to as Acute Coronary Syndromes (ACS). ACS ranges from unstable angina 
(reversible myocardial injury) to myocardial infarction with large areas of irreversible 
damage (cardiac necrosis) [18, 19]. As shown in figure 2, ACS is mainly divided into two 
categories based on changes in electrocardiogram presentation: ST-segment elevation 
myocardial infarction (STEMI) characterized by a fully occluded coronary artery and non-
ST-segment elevation ACS (NSTE-ACS) characterized by a partial or intermittently 
occluded coronary artery [18, 20-22]. 
 NSTE-ACS (more frequent) is also sub-categorized in unstable angina (UA) and 
non-STEMI. Both possess similar pathogenesis and clinical presentations. However, 
ischemia in non-STEMI is more severe in intensity and duration and causes irreversible 
myocardial damage. Thus, it is crucial to accurately categorize patients prior to treatment 
[1, 23]. 
         
Figure 2. Categories of ACS based on electrocardiogram findings: STEMI and NSTE-ACS 
(NSTEMI/UA). Adapted from [22]. 
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1.4. Diagnostic approach of Acute Myocardial Infarction  
 
AMI is essentially diagnosed by clinical symptoms, electrocardiogram (ECG) 
findings and elevated values of biochemical markers (biomarkers) of myocardial necrosis 
in the blood [24]. The diagnosis of AMI is indeed a truly challenging task. Symptoms include 
chest discomfort but also discomfort in other areas of the upper body, shortness of breath, 
sweating, nausea, vomiting and dizziness. However, a lot of these symptoms are not 
specific of myocardial ischemia. In addition, symptoms of AMI in critically ill patients may be 
masked by sedative or analgesic medications; these patients are also frequently unable to 
communicate ischemic symptoms because of endotracheal intubation or coma [25]. 
The ECG is the initial clinical test for diagnosing myocardial ischemia and infarction. 
ECG changes that occur in association with acute ischemia and infarction include peaking 
of the T waves, ST-segment elevation and/or depression, changes in QRS complex and 
inversion of the T waves. The evolution of AMI and the formation of AMI 
electrocardiographic characteristic waves are illustrated in Figure 3 [26-28].  
 
 
Figure 3. Evolution of AMI on the ECG. a) Normal, b) ST- segment elevation, c) Q wave formation 
d) T wave inversion, e) normalization with a persistent Q wave. Adapted from [28] . 
 
The earliest manifestations of myocardial ischemia are typically T wave and ST-
segment changes. In most patients with ST-elevation MyocardiaI Infarction (STEMI), clinical 
assessment and the ECG provide a straightforward diagnosis and allow the initiation of the 
proper treatment within minutes (Figure 4) [1, 16, 29]. Still, ECG alone is insufficient to 
diagnose AMI for two reasons: first, because ST segment deviation is observed in many 
other conditions [27]. Second, the diagnostic sensitivity of the initial ECG is about 50% for 
detecting myocardial damage, which means that many patients with AMI do not present 
significant ECG changes [30, 31]. 
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Thus, It is mandatory to collect biochemical markers from the blood for the accurate 
assessment of myocardial necrosis because symptoms and ECG findings may be 
insufficient to diagnose AMI [18, 32, 33]. 
 
 
Figure 4. Diagnostic approach of ACS. When there is no ST-segment elevation on the ECG, the 
diagnosis of AMI relies on biochemical markers of necrosis. When there is a rise/fall of the 
biochemical markers an AMI or non-STEMI (NSTEMI) is present otherwise it is Unstable Angina. 
Adapted from [1]. 
 
1.5. Biomarker evaluation 
 
A biomarker can be defined as a parameter that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention. A biomarker may be measured on 
a biosample (as blood, urine, or tissue test); it may be also a recording obtained from a 
person (blood pressure, Electrocardiogram) or even an imaging test (echocardiogram or 
CT scan) [34]. 
Cardiac biomarkers are protein components of cell structures that are released into 
the bloodstream when myocardial injury occurs. They play an important role in the 
diagnosis, risk stratification and treatment of patients with chest pain and suspected acute 
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coronary syndrome. The ideal characteristics for biomarkers of cardiac necrosis are 
summarized in table 1. [32] 
 
Table 1. Ideal characteristics of Cardiac Necrosis Biomarkers [32]. 
 Absolute cardiac specificity: Biomarkers should not be present in non-cardiac 
tissues under any physiological or pathological conditions.  
 Specific for irreversible injury: Biomarkers should differentiate ischemia from 
irreversible injury or necrosis.  
 Early release: Biomarkers should be released shortly after necrosis.  
 High tissue sensitivity: Biomarkers should be abundant in cardiac tissue and 
absent in blood under all pathological conditions except necrosis.  
 Stable release: Biomarkers should persist in circulation for hours to days, following 
the acute necrotic event.  
 Estimate of infarct size: Release of biomarkers should be in direct proportion to 
the extent of necrosis.  
 Measurable by conventional methods: Biomarkers should allow quantitative 
measurement by reliable, rapid, precise and cost-effective methodology that is 
readily available. 
 
Although several biomarkers satisfy one or more of these criteria, no single marker 
has yet been identified that satisfies them all [32]. The current gold-standard biomarker for 
the detection of myocardial necrosis are cardiac troponins (cTn), mainly cardiac troponin I 
(cTnI) and cardiac troponin T (cTnT) which have nearly absolute myocardial tissue 
specificity as well as high clinical sensitivity [35-37]. Several international scientific 
organizations such as the European Society of Cardiology (ESC), the American College of 
Cardiology (ACC), the American Heart Association (AHA), and the National Academy of 
Clinical Biochemistry (NACB) have recommended the use of these biomarkers when 
implementing new diagnostic strategies [18]. 
Troponin is an important protein of the thin filament (actin) of striated muscle and it 
is a complex of 3 subunits: C, T and I. Troponin T and I isoforms from the heart are 
structurally different from the corresponding forms found in skeletal muscle. The 
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measurement of cardiac troponin T and I isoforms is higher than other serum biomarkers of 
cardiac disease such as creatine kinase (CK) and myoglobin because they are also 
released in patients with skeletal muscle disease or injury [38, 39]. 
According to the last definition of AMI from the ESC, AHA and ACC, the detection 
of a rise and/or fall of cTn values is pivotal to the diagnosis of AMI [36, 40]. An increased 
value for cardiac troponin is defined as a measurement exceeding the 99th percentile of a 
normal reference population. The 99th percentile represents the decision level for the 
diagnosis of AMI and must be determined for each specific assay with appropriate quality 
control. [36, 40-43]. 
1.6. Market needs 
 
Traditional technologies for molecular diagnostics such as Enzyme-Linked 
Immunosorbent Assay (ELISA), Mass Spectrometry (MS) and Polymerase Chain Reaction 
(PCR) are typically limited to laboratory facilities, rely on sample purification, expensive 
cutting-edge instruments, and labour intensive procedures [44]. Furthermore, some of these 
technologies still lack the sensitivity for detecting trace levels of biomarkers and require long 
and tedious assay time. In most recent technologies, circulating levels of troponin still may 
not become detectable for up to 3 to 4 hours (Figure 5) [45]. 
The ultrasensitive detection of cardiac biomarkers is fundamental for AMI diagnosis 
since many important biomarkers are present at ultra-low concentrations, especially during 
the early stage of AMI. [24] Increases in sensitivity of troponin assays will undoubtedly 
lessen the number of potentially AMI missed or delayed diagnosis, thus decreasing mortality 
and morbidity rates and costs related with the actual burden of the disease [36, 46]. 
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Figure 5. Evolution of cardiac troponin (cTn) assays and their diagnostic cutoffs [49]. 
 
However, for the development of more sensitive assays, one should not only 
consider the increase in sensitivity but also in precision, because increases in sensitivity 
come inevitably with a decrease in specificity, resulting in more false-positive results. For 
instance, the replacement of a sensitive troponin assay (Siemens Healthcare Diagnostics) 
for a more sensitive one in the Bringham and Women’s Hospital Clinical Laboratories in 
early 2007 resulted in a doubling of positive troponin results in samples collected in the 
emergency department [45]. 
Increases in specificity are also important for the reliable exclusion of the disease in 
frequent dubious clinical settings. As a result, clinical uncertainties and unnecessary costs 
with overcrowding of emergency departments would be reduced with more straightforward 
diagnostic acuity. Accordingly, the use of a single biomarker may be insufficient to 
accurately categorize patients with acute coronary syndromes. Thus, the introduction of 
techniques that allow for the detection of multiple analytes simultaneously (multiplexing) 
may satisfy this constantly new growing need. Along with more diagnostic accuracy, 
multiplexing technologies enable lower sample consumptions, shorten turnaround times 
(time that goes from blood draw to test results reporting) and are more affordable in 
comparison with single-measurement assays [47-49].  
Recently, different biosensor platforms have been designed with potential for the 
detection of available cardiac biomarkers [50]. In comparison with laboratory-based large 
instruments, biosensing devices are generally rapid, sensitive, selective and user-friendly 
and do not require tedious pre-treatment of samples [51, 52]. 
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1.7. Biosensors 
 
The concept of biosensor was proposed in the 80s [53]. Today there are more than 
60 commercial devices available for about 120 different analytes. Among these are sensors 
for low molecular-mass substances, sensors for enzyme components and sensors for 
macromolecules. The current challenge is to design simple, inexpensive, accurate, 
sensitive and reliable biosensor platforms.  
A biosensor can be defined as an analytical device comprising three basic 
components: i) a target recognition unit used to capture the specific target  ii) a transducer 
that converts biorecognition events into quantifiable signals, iii) and a signal processing 
system that converts the signal into a readable form (Figure 6) [54-58]. 
The target recognition elements can be any chemical or biological components such 
as small organic molecules, proteins, antibodies, nucleic acids, carbohydrates, biological 
tissue and organelles [59-64]. The transducer system converts the biochemical reaction 
from the binding event into a physically detectable signal and can be divided into 
electrochemical, optical, piezoelectric, thermometric, ion-sensitive, magnetic or acoustic 
[55, 56, 59, 65]. 
 
Figure 6. Principle of Biosensors. First, there is a biorecognition event with the molecules of interest. 
The biorecognition event is then converted into a quantifiable signal (electric, optic, piezoelectric, 
etc) which is finally processed into a readable form [58]. 
 
The sensitivity of the biosensor for the target analyte is greatly influenced by the 
transducer, whereas the selectivity is mainly dependent on the recognition element [51]. 
The ideal biosensor not only has to respond to low-concentrations of analytes, but also must 
have the ability to discriminate among species according to the recognition molecules that 
Antibody 
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are immobilized on its surface [66]. Table 2 describes commonly used methods for 
bionsensing platforms [67]. 
 
Table 2. Currently employed methods for biosensing platforms: Electrochemical (widely 
seen in glucose monitors), mechanical and optical formats. Adapted from [67].  
Method Mechanism Features 
Electrochemical 
 
Detection of changes 
in electrical 
parameters at the 
active surface of 
electrodes that are 
proportional to the 
analyte concentration 
 
(+) Real-time detection 
(+) Low-costs of fabrication 
(+) Widely employed (glucose 
monitors) 
(-) Limited sensitivities 
(-) Short shelf-life 
(-)Temperature, pH and ionic 
concentration dependency 
Mechanical 
 
Detection of changes 
in mass on the sensor 
surface due to the 
binding of 
biomolecules 
(+) Label-free detection 
(-) Damping effects in liquid samples 
(-) Reduced sensitivity in liquids 
(-) Complex fabrication 
Optical 
Detection of variations 
in light intensity or 
refractive index 
changes 
(+) Minimal sample preparation 
(+) Easy-to-use 
(+) Ultra-low sensitivities 
(+) Found in every laboratory 
(-) Costly opto-instrumentation 
(-) Set-up complexity 
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1.7.1 Nanomaterials as transducer elements 
 
Nowadays it is well established that the performance of biosensors for the detection 
of biomolecules depends greatly on the influence of immobilization surfaces [68].  Among 
many immobilization surfaces, nanomaterials are being explored due to their exceptional 
optical and electrical properties, high surface-to-volume ratio, modified surface work 
function, high surface reaction activity, high catalytic efficiency and strong adsorption ability 
[69, 70]. 
Nanomaterial-based biosensors can achieve very low detection limits (even single 
molecule or cell) [71]. In addition they offer multi-detection possibilities and may ensure a 
high stability (more stable than enzymes or fluorescent dyes). Since nanomaterials have 
very high capacity for charge transfer they are likely to reach lower detection limits and 
higher sensitivity values. The microenvironment provided by a nanomaterial may help a 
biomolecule to retain its conformation with maximum biological activity [55, 70-72]. 
Metallic nanoparticles (NPs) such as gold (AuNPs) and silver (AgNPs) nanoparticles 
in particular, have attracted significant attention in the fields of biosensing and are preferably 
described in this thesis [73]. 
1.7.2 Metallic NPs 
 
The unique physical and chemical properties of noble metal NPs have contributed 
to the development of new biosensing platforms with improved capabilities for the specific 
detection of bioanalytes [69]. Metallic NPs can be described as a lattice of ionic cores with 
conduction electrons moving almost freely inside [74]. Metallic NPs have an average size 
typically between 1 and 100 nm (100 to 1000 times smaller than human cells), which display 
unique optical properties different from those observed in the bulk materials [75].   
When the size of the metallic NPs is reduced to a few nanometers, these optical 
properties are strongly enhanced due to what is called the Surface Plasmon Resonance 
(SPR) effect [76]. Basically, the phenomenon is characterized by a collective oscillation of 
the conduction electrons to the surface of the nanoparticle due to a “force” exerted by the 
electromagnetic field. As a consequence of the confinement of the electrons inside the 
nanoparticle, negative charge will be accumulated in one side and positive charge in the 
opposite one, creating an electric dipole. This dipole generates an electric field inside the 
nanoparticle, opposite to that of the light, compelling the electrons to return to the 
equilibrium position (Figure 7) [76-79]. 
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Figure 7. Illustration of the localized surface plasmon resonance effect and formation of an electric 
dipole [79]. 
 
 In the particular case of AuNPs and AgNPs, the SPR effect yields exceptionally high 
absorption and scattering properties that allows them to have a higher sensitivity in optical 
detection methods than conventional organic dyes [69]. The SPR frequency is highly 
sensitive to the shape, size and composition of the nanoparticles, inter-particle distance and 
dielectric nature of its interface with the local environment, thus providing an effective way 
for tuning their optical properties (Figure 8) [79-84]. 
 
 
Figure 8. Modulating SPR properties of colloidal gold (a) and silver (b) solutions with variations in 
nanoparticle size and shape, respectively [83, 84].  
 
The bright and distinct colours possessed by noble metal NPs are due to the SPR resulting 
from the collective oscillations of conduction band electrons excited by light of appropriate 
frequencies [85]. The Plasmon resonance property of AuNPs makes them most suitable 
engineered nanomaterials for bioimaging, biomedical therapeutics and biodiagnostic tools 
[86, 87]. For instance, biomolecule-conjugated AuNPs are largely used as biomarkers and 
biodelivery vehicles in medicine [88], pharmacy [89] and in cosmetic products [90]. What 
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makes AuNPs so desirable for medical applications over other metal nanoparticles is their 
inertness, less cytotoxicity, biocompatibility and also the easy surface modification with 
different biomolecules such as peptides, proteins and nucleic acids [70, 80, 91].  
On the other hand, AgNPs have also attracted worldwide research interest due to 
their unique physical and chemical properties which lead to numerous potential applications 
in optical, electrical and biological industries [92]. For instance, they can be used as 
catalysts [93], sensors and biosensors [94], and antimicrobial agents [95].  
AgNPs play a crucial role in inhibiting bacterial growth in aqueous and solid medium 
due to their high reactivity. The antibacterial properties of the silver-containing materials can 
be applied, for example, in medicine to reduce infections as well as to prevent bacteria 
colonization on medical instruments [96].  
  Silver exhibits the highest efficiency of plasmon excitation among the three metals 
(silver, gold and copper) that display SPR bands in the visible spectrum [97]. Moreover, 
optical excitation of plasmon resonances in AgNPs is the most efficient mechanism by 
which light interacts with matter. A single silver nanoparticle interacts with light more 
efficiently than a particle of the same dimension with any organic or inorganic chromophore. 
AgNPs capture much more light than is physically incident on them due to higher light-
interaction cross-sections [97].  
For these reasons, Au and Ag NPs were strategically chosen to be the transducer 
elements of the envisaged biosensor.  
1.7.3 Synthesis of metallic NPs 
 
Two complementary approaches have been known for the preparation of 
nanostructures: the first is the breakdown method (top-down) and the second is the build-
up method (bottom-up) [98]. The top-down method typically uses advanced lithographic, 
milling and grinding technologies which reduce the dimensions of macro-scaled metals into 
smaller particles from the micrometer to the nanometer regimen followed by stabilization of 
the resulting nanosized metal particles by the addition of colloidal protecting agents [98, 
99]. In the bottom up approach, smaller components of atomic or molecular dimensions 
self-assemble chemically to give rise to a larger and more organized system. Therefore, 
bottom-up strategies employ the chemical or electrochemical reduction of metal salts in 
solution (Figure 9) [100, 101]. 
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Figure 9. Illustration of the two complementary approaches for the preparation of nanostructures: 
Top-Down and Bottom-Up. Adapted from [101]. 
 
The chemical reduction method is one of the most used methods to prepare metallic 
NPs, in which metal salts are reduced to their metal states with reducing agents such as 
sodium citrate (Na3C6H5O7) and borohydride (NaBH4)  [102]. For instance, AuNPs are 
commonly prepared by the reduction of hydrogen tetrachloroaurate (H[AuCl4]) with sodium 
citrate solution, wherein gold ions Au3+ are reduced to neutral gold atoms Au0 [69, 103]. The 
citrate reduced Au colloidal solution has a red wine colour with an absorption in the visible 
region of approximately 520 nm [104]. This methods usually yields AuNPs in the 10–20 nm 
diameter range with relatively narrow size distributions [97]. 
On the other hand, AgNPs can be synthesized by following the methods used for 
AuNPs by replacing the gold salt with silver nitrate (AgNO3) [75]. In this case, sodium 
citrates reduces silver ions (Ag+) to metallic silver (Ag0).The citrate reduced Ag colloidal 
solution has a yellow colour with an absorption maximum in the visible region of 420 nm 
[75, 92]. AgNPs prepared by the citrate reduction are nearly spherical and the crystallites 
have relatively large diameters (50–100 nm) and wide range distributions in size and shape 
[105, 106]. 
The advantages of the chemical reduction method include the facile fabrication of 
particles of various shapes along with narrow size distributions, the use of non-complicated 
equipment or instruments and the yield of large quantities of NPs in short time at low costs 
[107]. Moreover, it is possible to fine-tune the shape and size of the NPs by changing 
parameters such as the reducing agent, the reaction time and the temperature [107, 108]. 
 In the process of chemical reduction, metal NPs require protective agents for 
stabilization and to prevent particles from sticking together by Van der Waals and 
electrostatic interactions (aggregation) in order to maintain its nanoscale properties. The 
two basic modes of stabilization which have been distinguished are electrostatic and steric. 
Electrostatic stabilization is based on the electrical double layer repulsion between the 
particles. (Figure 10) [109, 110]. Typically, the layer of adsorbed citrate anions at the surface 
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of AuNPs and AgNPs prevents aggregation due to electrostatic repulsion, keeping particles 
away from each other [111]. Therefore, sodium citrate acts both as a reducing and a 
stabilizer agent [108]. 
 
 
Figure 10. Electrostatic repulsion. Particles in suspension that possess, in this case, negative 
charges at the surface will tend to repel each other and there will be no tendency to form aggregates. 
Adapted from [110]. 
 
Another stabilization mechanism is based on the steric repulsion between molecules 
or ions adsorbed on neighbouring particles. [112]. Typically, long chains of organic 
molecules are used to provide a particular effective stabilization by acting as protective 
shields on the metallic surface. Thus, NPs are separated from each other and aggregation 
is prevented (Figure 11)  [109, 113]. Size and chemical nature of these molecules determine 
the degree of stabilization. Polymeric compounds such as polyvinylalcohol (PVA), 
polyvinylpyrrolidone (PVP), polyethyleneglycol (PEG), polymethacrylicacid (PMA), and 
polymethylmethacrylate (PMMA)  for instance are prime candidates for steric stabilization 
of nanoparticles [113, 114]. 
 
 
Figure 11. Steric stabilization. Long polymer chains and the arrangement of conical geometries on 
metal surfaces provide effective steric stabilization. Adapted from [109].  
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1.7.4 Aptamers as biorecognition elements 
 
The specific detection of cardiac troponin I can be achieved with the incorporation 
of aptamers as biorecognition elements for the proposed biosensor. The term “aptamers” 
results from the combination of two words: “aptus” (meaning to fit) and the Greek word 
“mers” (particle) [115, 116]. Aptamers are small single-stranded molecules of RNA or DNA 
(oligonucleotides) that bind with extremely high specificity to various molecular targets such 
as small molecules, proteins, nucleic acids, cells or microorganisms [117, 118]. They are 
isolated and chemically synthesized in vitro from huge combinatorial libraries by a process 
known as Evolution of Ligands by Exponential Enrichment (SELEX) [57, 119]. 
The selection process starts when random sequences of 1014-1015 oligonucleotide 
strands are chemically synthesized and amplified with Polymerase Chain Reaction (Figure 
12). The nucleic acid library is incubated with a target molecule, often immobilized onto a 
solid state matrix such as gel or a column, so that the DNA or RNA which has affinity to the 
target molecule can be captured. The nucleic acids that bind to the target are then separated 
from the unbound strands and eluted from the target molecule for a new stage of 
amplification via PCR. After each round of selection there will be a new library of nucleic 
acid molecules containing more affinity to the target. The next rounds of selection are 
usually performed under more stringent conditions such as lower concentration of the target 
and shorter time for binding. Finally, the oligonucleotide that has higher affinity to its target 
molecule is obtained approximately after 10-20 cycles of the selection process [57, 120-
124]. 
 
Figure 12. In the first step random DNA or RNA oligonucleotides and the target are incubated for 
binding. Unbound oligonucleotides are removed by several washing steps. The target-bound 
oligonucleotides are eluted and subsequently amplified by PCR [124]. 
Chapter 1 - Introduction 
 
20 
 
 
The combination of metallic NPs with aptamers represents an incredible 
breakthrough innovation since there is nothing like it in the market. All the processes known 
in the market are based on immunoassays in which antibodies are targeted to cardiac 
biomarkers [125]. The problem with antibodies is that they are more expensive, need 
stringent storage and handling conditions and often require animals and cell cultures to be 
produced [126, 127]. Aptamers, on the contrary, exhibit several unique features in 
comparison with natural receptors such as enzymes and antibodies which include:  
 
 Binding efficiency: Aptamers with higher affinity and specificity can be selected in vitro 
for any given target, not only large molecules such as proteins and cells but also to small 
molecules such as nucleotides, organic dyes, amino acids and metal ions whereas 
antibodies are generally competent in binding to mostly larger molecules [116, 126]. 
 
 Chemical stability: It is well known that proteins easily undergo irreversible 
denaturation and so lose easily their tertiary structures at high temperatures. On the 
other hand, oligonucleotides are more thermally stable and maintain their structures 
over repeated cycles of denaturation/renaturation [128]. 
 
 Production: The identification and production of monoclonal antibodies are laborious 
and very expensive processes involving screening of a large number of colonies. The 
clinical commercial success of antibodies has led to the need for very large-scale 
production in mammalian cell culture. Aptamers in contrast, once selected can be 
obtained in large amounts through chemical synthesis with great accuracy and 
reproducibility. These chemical processes are more cost-effective than the production 
of antibodies [128]. 
 
 Target-reaching efficiency: Aptamers can penetrate tissues faster and more efficiently 
due to their significantly lower molecular weights (8-25 kDa aptamers versus ~150 kDa 
antibodies). Therefore, aptamers penetrate barriers and reach their target sites in vivo 
more efficiently than the larger-sized protein antibodies [129].  
 
 Immunogenicity: Aptamers are virtually non-immunogenic in vivo, which means that, 
in principle, they are not recognized by the immune system. Antibodies, on the contrary, 
are highly immunogenic since they stimulate an immune response in vivo [129]. 
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 Flexibility: It is easy to chemically modify aptamers with a variety of tags or functional 
groups such as primary amine (NH2) and thiol (SH) groups on either 5’ or 3’ ends, on 
the bases or on the backbone of DNA [120, 130]. 
 
1.7.5 Functionalization of aptamers onto metal NPs  
 
Functionalization of NPs is necessary for their stability, functionality and 
biocompatibility  [70]. Commonly used functionalization strategies are based on the use of 
Polyethylene glycol (PEG), oligonucleotides, peptides, antibodies and similar molecules 
[131-134]. Functionalization of metallic NPs involves the use of bifunctional ligands in which 
a moiety (-SH, -NH2, -COOH) is used for anchorage to the NPs while the other is directed 
to the outer-surface for specific interaction with biomolecules [104]. Bifunctional ligands 
containing SH or NH2 groups at one of their ends are preferred because they are prone to 
form strong gold-sulphur (Au-S) and gold-nitrogen (Au-N) bonds at the surfaces of metallic 
NPs [70]. 
The ultimate goal in functionalization is to preserve the properties of both metallic 
NPs and the bound biological molecules, which means that biological molecules should be 
stable and able to retain its biorecognition properties and metal NPs should be able to retain 
its unique properties such as strong Plasmon absorption bands, light scattering, among 
others [135, 136]. 
The key step for any aptamer-based sensor design involves the immobilization of 
the aptamer to the surface of the sensor. Physical adsorption, based on ionic, hydrophobic 
and Van der Waals forces, is the simplest immobilization method since it does not require 
any nucleic acid modification. It consists in contacting the aptamer solution with the surface 
for a defined period of time followed by subsequently washing steps for the removal of any 
non-adsorbed biomolecules. However, physical adsorption suffers from biomolecule 
desorption from the surface due to weak and reversible binding [136, 137]. 
Another non-covalent easy way to functionalize and stabilize metallic nanoparticle-
bioconjugates is through electrostatic interactions between the metallic NPs and the 
biological molecules. For instance, positively charged metallic NPs can bind by stable ionic 
interactions to negatively charged functional groups [135]. 
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Likewise strong negative charge on the citrate-stabilized AuNPs surface provides 
opportunity for electrostatic interaction with positively charged amine groups (NH2) of lysine 
residues of proteins adsorbed on the nanoparticle surface [135, 138, 139]. 
On the other hand, methods based on chemisorption or covalent linkages have been 
widely employed. For example, aptamers labeled with a thiol group at one end can be easily 
chemisorbed onto the surfaces of AuNPs [59] whereas amine-labeled aptamers can be 
easily adsorbed on the surface of carboxyl-modified silica nanoparticles (SiNPS) [122] 
Thiol-based aptamers are most commonly used to prepare functionalized AuNPs through 
strong Au-S bonding [59]. Advantages of using a direct Au-S bond to attach a receptor 
molecule include a rapid covalent reaction and a formation of a stable monolayer [140]. 
1.7.6 Optical biosensing techniques 
 
Optical detection techniques are currently regarded as the most sensitive 
techniques, allowing sensitivities down to nanomolar-femtomolar (10-9-10-15) [24]. Optical 
biosensors can be classified into colorimetric, fluorescence, luminescence and surface 
plasmon resonance [67]. 
In colorimetric and fluorescence-based detection either target or biorecognition 
molecules are labeled with chromogenic/fluorescent tags such as dyes. The change in the 
intensity of the color/fluorescence signal indicates the presence of the target molecules and 
the interaction strength between target and biorecognition molecules [50, 141]. 
Fluorescence detection is the most commonly used optical technique for the detection of 
biomolecules because of its high sensitivity and low detection limits [142]. However, 
fluorescence suffers from laborious labeling processes that may also interfere with the 
function of the biomolecule [142]. The sensitivity of fluorescence detection is often 
compromised by background signals coming from autofluorescence of sample components. 
Quantitative analysis is also challenging since fluorescent dyes on each molecule cannot 
be precisely controlled. Additionally, fluorescent dyes are costly, have a limited shelf-life 
and are often dependent on pH [67, 141].   
The luminescence methods are widely categorized into two types, namely 
chemiluminescence and electroluminescence. In chemiluminescence, target binding 
causes photochemical reactions, either directly or with the help of an enzyme label (Figure 
13) [67, 143]. In electroluminescence, the luminescence signal is generated by an electron 
transfer reaction of a luminescent compound immobilized near the proximity of an electrode 
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surface [50]. These techniques have distinct advantages such as the absence of light 
sources, which contribute to minimize scattered light and luminescent impurities.  
Yet, highly sensitive detectors are usually extra-demanded to analyze the emitted photons 
during chemiluminescent reactions. Thus, low-cost sensitive photodetectors are still needed 
for the adoption of luminescence-based biosensors [67]. 
 
 
Figure 13. Illustration of a chemiluminescence method. The secondary antibody containing an 
enzyme label is conjugated to the primary antibody. A certain enzyme catalyzes the 
chemiluminescent substrate to produce light. Light is then measured with an external equipment 
called a luminometer [143]. 
 
Recently, Surface Plasmon Resonance (SPR) has become the preferred label-
free optical method. When molecules with sufficient mass bind to the surface of noble 
metals, they disturb the plasmon and shift the resonance angle of an incident light. These 
shifts consist on minute refractive index changes on the surface and so can be used to 
detect the binding of mass to the surface (Figure 14) [144, 145]. While very powerful, the 
SPR technique relies solely on the ability of biomolecular recognition elements to recognize 
and capture target analytes. Therefore, the accuracy of SPR measurements can be 
compromised by interferences which produce a change in the refractive index but are not 
associated with the capture of the target. One source of interferences is non-specific 
interactions between the sensor surface and the sample, including adsorption of non-target 
molecules to the surface of the sensor and binding of structurally similar but not target 
molecules to the biomolecular biorecognition elements. Other interferences may occur for 
example from background refractive index changes such as sample temperature and 
composition fluctuations [142, 146, 147].  
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Figure 14. (a) A polarized light is applied to the surface of the sensor chip and is reflected. The 
intensity of the reflected light is adjusted to a certain incident angle, the SPR angle. (b) Interacting 
substances near the surface of the sensor chip increase the refractive index, which alters the SPR 
angle [145]. 
1.8. Surface enhanced Raman Scattering Spectroscopy  
  
To address some of the limitations of current optical techniques Surface enhanced 
Raman Scattering spectroscopy (SERS) has recently awaken considerable interest for both 
in vitro and in vivo medical diagnostics [148-150]. SERS is an extension and variation of 
standard Raman Spectroscopy, a vibrational spectroscopic technique that provides detailed 
information about the interrogated substances at the molecular level [151]. 
Briefly, the Raman spectroscopic technique involves shining a laser source onto an 
unknown chemical sample. Most of the light that is absorbed by the sample will be scattered 
back at the same wavelength of the laser source. Thus, only a small portion of the light that 
is absorbed will be scattered at different wavelengths that are indicative of the vibrational 
transitions in the molecule. Since different molecules possess different vibrational modes, 
the spectrum of the inelastically scattered light can be thought as analogous to a molecular 
fingerprint. Despite this high specificity, traditional Raman Spectroscopy was considered 
limited because of the relatively weak signals and small scattering cross-sections [142, 
152].  
Nevertheless, this problem was mitigated with the advent of SERS in the late 1970s 
by showing that Raman signals could be enhanced by several orders of magnitude in the 
presence of nanostructered metal surfaces [148, 152-155]. This enhancement can be 
explained by two mechanisms: a) electromagnetic mechanism (EM) associated with large 
local fields caused by electromagnetic resonances occurring near metal surface structures 
and b) chemical mechanism (CM) involving a scattering process associated with chemical 
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interactions between the molecule and the metal surfaces. The electromagnetic mechanism 
is believed to contribute the most (104-107) to the observed intensity enhancement 
conversely to the chemical mechanism (10-102) [156, 157]. 
The huge local electromagnetic field enhancement is presumably from the so called 
Hot-Spots, spatially localized surface Plasmon resonances occurring between two or more 
closely spaced metal nanostructures [158]. It is believed that Hot-Spots are responsible for 
the single molecule (SM) sensitivity of SERS [159]. Nie’s group [160] and Kneipp’s group 
[161] have reported single molecule detection by SERS, indicating the high sensitivity of 
SERS for ultrasensitive chemical or biological detection. Moskovits’s group has recently 
reported the detection of DNA by SERS based on EM Hot-Spots, further indicating the ability 
of SERS for the ultra-sensitive detection of biological molecules [162-164]. 
In addition to high sensitivity at single molecule, SERS offers the possibility for 
detection of multiple analytes at single excitation wavelengths because of the very narrow 
spectral widths of Raman peaks (typically 10-100 times narrower than fluorescence peaks) 
[148, 165, 166]. Nowadays there are two main SERS configurations for biosensing 
platforms: intrinsic or extrinsic [167]. In intrinsic detection, the analyte can be directly applied 
to the nanostructured surfaces and the Raman spectrum of the biomolecule directly 
measured to identify the specimen [151]. In extrinsic detection, antibodies, nucleic acids or 
related molecules can be immobilized onto metallic nanostructured surfaces in order to aid 
for capture and specific detection of the molecule of interest. (Figure 15) [151, 168].  
              
Figure 15. Extrinsic configuration of SERS for biosensing platforms. Adapted from [168]. 
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The extrinsic SERS detection method with aptamers has been reported for the sensitive 
detection of thrombin (an enzyme involved in the coagulation process) [127, 162]. Based 
on the fact that thrombin can bind two Thrombin Binding Aptamers (TBA) at the same time, 
Wang et al., reported an aptamer sandwich complex composed by TBA/ thrombin/ TBA-
AuNPS as shown in Figure 16. [162] In this approach, the EM coupling effect was produced 
by Hot-Spots between AuNPs and AgNPs, where the Raman probes reside. Au substrate 
was bound to the 5’ thiolated TBA and thrombin was then bound to the TBA through one of 
the active sites. AuNPS labeled by TBA and Raman probes were then bound to the thrombin 
immobilized on the Au substrate through the other binding site of thrombin. The detection 
limit of this SERS aptasensor was 5×10-10M.  
 
 
Figure 16. Schematic illustration of a SERS aptasensor for thrombin detection. TBA bounds to the 
Au substrate with a thiol group at the 5’ end and leaves another active site for binding with thrombin. 
AuNPs labelled with TBA and Raman probes were then bound to the thrombin immobilized on the 
Au substrate through the other binding site of thrombin. AgNPs were employed to enhance the signal 
of the Raman probes due to the EM coupling effect between AuNPs and AgNPs. Adapted from [162] 
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1.9. Objectives 
 
The first objective of this work is dedicated to the synthesis and characterization of 
metallic NPs with different sizes and nature (Au and Ag). This step is very important to 
select the optimal structural and morphological characteristics for the detection of human 
cardiac troponin I.  
The second objective aims for the detection of human cardiac troponin I with an 
intrinsic SERS configuration. The idea is to simply apply the supplied cardiac troponin I at 
low concentration on the surface of Au and Ag NPs (for comparison) followed by a stringent 
analysis of the resulting spectrum. SERS can provide a lot of information about protein 
structure, orientation and environment that needs to be addressed and primarily understood 
since there is still much to know about cardiac troponin I.   
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2. Synthesis and characterization of metallic NPs 
2.1. Citrate reduction method  
 
AuNPs were prepared by the reduction of hydrogen tetrachloroaurate (H[AuCl4]) 
with sodium citrate solution, accordingly with the method first developed by Turkevich [1] 
and AgNPs were prepared by the reduction of silver nitrate (AgNO3) also with sodium citrate 
solution.   
For the characterization of the as-prepared metallic NPs, several techniques such 
as optical spectroscopy, vibrational spectroscopy, microscopy analysis and others were 
employed in order to have further evidence about their size, size distribution, shape and 
stability in aqueous solution.  
Firstly, metallic NPs (Au and Ag) were characterized by optical measurements. The 
formation of Au and Ag NPs was followed by measuring the absorption of the solutions at 
wavelengths ranged from 300-800 nm. Figure 17 shows the optical spectra of the metallic 
NPs, where absorption bands at 428 and 520 nm, characteristic of the SPR band of AgNPs 
and AuNPs, respectively can be observed.  
 
 
Figure 17. UV-VIS spectrum of Au and Ag NPs.  
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The intense peak at 520 nm for AuNPs can be attributed to the surface plasmon 
excitation of small spherical AuNPs. On the other hand, AgNPs presented a broad 
absorbance band with a maximum at 428 nm, indicating larger sized AgNPs with a wide 
size distribution.  
The metallic NPs were also characterized by spectroscopy analysis such as Fourier 
Transform Infrared spectroscopy (FTIR) to study the molecular species attached at the 
surface of Au and Ag NPs (Figure 18). 
 
Figure 18. FTIR spectrum of synthesized Au and Ag NPs, indicating the adsorption of sodium citrate 
onto their structures through the presence of carboxylate symmetric and asymmetric stretching 
vibrations from citrate at ~1382 cm-1 and around 1500-1630 cm-1, respectively.  
 
The bands at ~1382 cm-1 and around 1500-1630 cm-1 are assigned as the 
carboxylate symmetric and asymmetric stretching vibrations from citrate, respectively 
[vsym(COO-), vasy(COO-)]. The presence of two distinct symmetric and asymmetric stretching 
vibrations, vsym(COO-) - vasy(COO-), is indicative of the binding character of a carboxylate 
group with a metal ion, suggesting the coupling of citrate onto the surface of Au and Ag 
NPs. The band between 3550-3300 cm-1corresponds to a characteristic stretching vibration 
of OH- groups due to adsorbed water (H2O) [2].  
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For the assessment of the stability of the colloids, Zeta Potential values were 
measured and were found to be -51.2 mV and -39.4 mV for Au and Ag NPs, respectively 
(Table 3). The negative Zeta potential measurements are due to the capping of citrate ions 
on the surface of metal structures. Both colloids (Au and Ag NPs) are stable accordingly 
with these results.  
                   
Table 3. Zeta Potential measurements. 
  ζ (mV) pH 
AuNPs -51.2 5.3 
AgNPs -39.4 7.4 
 
 
The size and shape of the noble metal NPs were verified by Transmission Electronic 
Microscopy (TEM). Figure 21 presents the TEM micrographs of Au (a) and Ag NPs (b). 
 
 
Figure 19. TEM micrographs of Au (a) and Ag NPs (b). 
 
AuNPs synthesized by the citrate reduction method (Figure 19.a) exhibit indeed 
spherical and uniform-sized particles. The size distribution histogram obtained from the 
micrographs of the particles (Figure 20.a), fitted with a Gaussian curve, registered a mean 
diameter and standard deviation of 14.4 nm and 2.4 nm, respectively. Particles with 
diameters longer than 20 nm could have been resulting from some aggregation during 
preparation of the TEM holding grid.  
 
  
(a) (b) 
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AgNPs (Figure 19.b) also show nearly spherical morphology, but the size is bigger 
than AuNPs. The particle’s size distribution histogram obtained from the micrographs 
presented a mean diameter of 54.2 nm and a standard deviation of 17.6 nm, respectively. 
As shown in the particle size distribution histograms (Figure 20.b), AgNPs present broad 
size distributions with particle sizes ranging from 20 to 100 nm.  
 
Figure 20. Particle size distributions of Au (a) and Ag NPs (b) using sodium citrate as the reducing 
agent. 
        
The average number of Au and Ag atoms per nanoparticle (N) may be calculated from TEM 
analysis by knowing that N=31d3 according to Liu et al., where d is the average core 
diameter (nm) of the nanoparticle obtained from the micrographs [3]. The molar 
concentration of AuNPs and AgNPs (C) was then calculated by dividing the total number of 
Au and Ag atoms added to their respective reaction solutions (Ntotal) over the average 
number of Au and Ag atoms per nanoparticle (N), following the equation (1)  
 
 
𝐶 =
𝑁𝑡𝑜𝑡𝑎𝑙
𝑁𝑉𝑁𝐴
       (1) 
 
V is the volume of the reaction solution and NA the Avogadro’s constant (~6.02×1023).It was 
estimated a concentration of 1.24×10-8 M for AuNPs and 2.02×10-10 M for AgNPs.  
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2.2. Seed-mediated growth 
 
The need for synthesizing AuNPs with larger sizes, required the use of a slightly different 
synthetic route. The presented procedure consisted in the synthesis of AuNPs through the 
mediated-seed growth method, by using sodium citrate and ascorbic acid as reducing 
agents. In this procedure, smaller particles acted like seeds for later particle enlargement. 
The increase in the size of AuNPs can be witnessed by the change in the colour of the 
colloids which goes from cherry-red in the first step, through ruby-red in the second to a 
light pink in the last growth step (Figure 21).  
 
Figure 21. AuNPs obtained experimentally via seed growth method. 
 
UV-VIS and microscopy analysis were performed to study the size and morphology 
of the synthesized AuNPs. Figure 22 shows the UV-VIS absorbance of AuNPs obtained at 
different growth steps. 
 
 
Figure 22. UV-VIS spectra of AuNPs at different growth steps (seeds, G1 and G2). 
                       
 
Growth 
Chapter 2 – Synthesis and characterization of metallic NPs 
 
 
44 
 
The sharp absorbance peaks for the Au seeds and for the first growth step, G1, 
located nearly at 520 nm and 527 nm, respectively, are caused by the presence of small 
and uniform-sized spherical NPs with narrow size distributions. In the second growth step, 
G2, absorbance shows a red shift of ∼50 nm, indicating a considerable increase in the size 
of AuNPs.   
Although the size and shape of NPs is generally determined by TEM, UV-VIS 
spectra can also be used to obtain preliminary estimates of the size and concentration of 
NPs in aqueous solutions [4]. 
The size and concentration of AuNPs can be calculated with reference to Haiss et 
al [5]. According to Haiss, when AuNPs have diameters smaller than 35 nm, the ratio of the 
absorbance at the SPR peak to the absorbance at 450 nm can be used to determine the 
particle size without knowing the concentration using the following equation:  
 
𝑑 = 𝑒𝑥𝑝 (𝐵1
𝐴𝑠𝑝𝑟
𝐴450
− 𝐵2)          (2) 
 
where Aspr/A450 is the ratio of the absorbance at the surface plasmon resonance peak (Aspr) 
to the absorbance at 450 nm (A450), B1 = 3.00 and B2 = 2.20 and d is the diameter.  
For NPs with sizes ranging from 35 to 120 nm, Haiss presents a different equation:  
𝑑 =
𝑙𝑛(
𝜆𝑠𝑝𝑟−𝜆0
𝐿1
)
𝐿2
      (3) 
 
where d is the diameter of a nanoparticle, and λspr is the plasmonic peak wave. λ0 = 512, L1 
= 6.53 and L2 = 0.0216 are fitting parameters determined from the theoretical values.  
The concentration of AuNPs was also determined by using the diameters estimated in (2) 
and (3) and accordingly with the literature [4, 5]. Table 4, summarizes the results obtained 
from the UV-VIS spectra. 
 
Table 4. Results obtained from UV-VIS following Haiss equations. 
Growth 
step 
Diameter 
(nm) 
Concentration 
(NPs/ml) 
Concentration 
(Mol/l) 
SPR peak 
(nm) 
Aspr A450 
Seeds 14.3 1.5 × 1012 2.3 × 10-4 520 0.76601 0.47145 
G1 38.5 6.2 × 1010 1.8 × 10-4 527 0.88753 0.44421 
G2 104.9 4.0 × 109 2.4 × 10-4 575 1.08437 0.46574 
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Figure 23 illustrates Transmission Electron Microscopy (TEM) and Scanning Transmission 
Electron Microscopy (STEM) micrographs of the as-prepared AuNPs together with the 
particle size distribution histograms generated from the micrographs.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. (a) TEM micrograph of Au seeds; (b) STEM micrograph of AuNPs of the first growth step, 
G1; (c) TEM micrograph of AuNPs of the second growth step. The insert is a higher magnification 
micrograph of AuNPs of the second growth step with a scale bar of 100 nm.  
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Au seeds present uniform sizes and narrow size distributions as confirmed by TEM 
micrographs and respective particle size distribution histogram (Figure 23.a). They 
exhibited spherical shapes with an average diameter of 15.1 nm (standard deviation of 2.9).  
AuNPs of the first growth step continued to demonstrate good spherical shapes and 
narrow size distributions (particle sizes range mainly from 29 to 50 nm). (Figure 23.b) The 
size of the nanoparticle found in STEM was 37.5 nm (standard deviation of 4.4), which is in 
good agreement with the calculated value (38.5 nm) in reference to Haiss.  
Finally, TEM confirmed that AuNPs of the second growth step are not quite spherical 
at this stage but instead present some facets and edges. These NPs have a particle mean 
size of 96.2 nm (standard deviation of 8.0), approximately 8 nm smaller than the theoretical 
value obtained with the Haiss calculations (Figure 23.c) There is also a broadening of the 
particle size distribution, which is congruent with the wide absorbance peak obtained from 
the UV-VIS analysis.  
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“I have not failed 700 times. I have not failed once. I have succeeded in proving that those 
700 ways will not work. When I have eliminated the ways that will not work, I will find the 
way that will work.” 
Thomas Edison 
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3. Results and discussion 
 
In a first approach it was performed a simple and direct label-free detection method 
by applying cardiac troponin I onto the surface of Au and Ag NPs. This step is of crucial 
importance because allows to investigate structural aspects of the full-length cardiac 
troponin I that are absent of any XRD data and less studied from a surface chemistry and 
spectroscopy perspective. Additionally, an exhaustive study of its spectrum allowed to 
understand inherent biodetection issues that will be of great value for future optimization of 
experimental conditions.  
The SERS spectrum provides a fingerprint which represents the set of bonds 
present in the protein. The vibrational frequencies are characteristic of the chemical bonds 
and groups of bonds between different amino acids (the building blocks of peptides and 
proteins). These vibrational frequencies are sensitive to details of the structure and local 
environment of the protein such as symmetry, crystal phase, interaction and orientation, etc 
[1]. For instance, groups in the protein such as the carboxyl group (COOH) or amino groups 
(NH2) interact with the metal surfaces, giving strong enhancements of these bands. Other 
spectral features of proteins typically include bands from aromatic side chain vibrations of 
amino acids like tyrosine, tryptophan and phenylalanine and also from disulphide bridges 
(S-S) between pairs of cysteine residues [2]. 
Disulphide bonds in proteins are covalent bonds formed between thiol groups (-SH) 
present in cysteine residues (Figure 24). S-S bonds are essential for the functional 
properties of proteins and are key elements in the stabilization of tertiary structures [3, 4]. 
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Figure 24.Thiol groups of free pairs of cysteine residues can form disulphide bonds (S-S), playing a 
major role in protein tertiary and quaternary structures.  
Since certain amino acids such as cysteine contain thiol groups within its structures, 
these compounds could be easily chemisorbed onto the surface of metallic NPs due to high 
affinity with metal, thus providing strong enhanced bands in the spectra. Hence, it was 
expected that the presence of cysteine residues would be favourably observed in the 
spectra of both metallic NPs.  
SERS analysis started with the addition of cardiac troponin I onto the surface of the 
colloids (Au and Ag) synthesized via citrate reduction method. The spectra of the substrates 
were also recorded in SERS prior to the detection of the protein on each assay to better 
perceive spectral differences that are only derived from the protein. 
Figure 25 displays the SERS spectra of cardiac troponin I onto the surface of 15 nm 
AuNPs.  
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Figure 25. Spectra of cardiac troponin I onto the surface of AuNPs (blue colour). The spectra of the 
colloid (red colour) was also performed as a reference.  
 
After observation of the spectra, it is possible to confirm that there is no single peak 
formation and therefore no evidence of detection of cardiac troponin I. The spectra of 
cardiac troponin I exhibits plenty of noise and it is substantially equivalent to the spectra of 
the substrate alone which indicates the inexistence of some sort of detectable signal from 
the protein. 
 On the other hand, when cardiac troponin I was applied directly to the surface of 50 
nm AgNPs synthesized similarly by the same method the response was different. In this 
case, it is possible to observe intense bands nearly at 400, 630, 720, and 1009 cm-1 (Figure 
26).  
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Figure 26. Spectra of cardiac troponin I onto the surface of AgNPs (green colour). The spectra of 
silver colloids was considered as a reference. 
 
These results are not conclusive so far in part because cardiac troponin I was 
acquired within a considerable amount of a preservative stabiliser known as 2-
mercaptoethanol. 2-Mercaptoethanol is used to break disulphide bonds (S-S) in proteins, 
leading to the disruption of both quaternary and tertiary structures [5]. 2-Mercaptoethanol is 
often included in several enzyme assays as a standard buffer solution to maintain protein 
activity by inhibiting oxidation (loss of H+) of free sulfhydryl residues [6]. Figure 27 illustrates 
the mechanism of cleavage of disulphide bonds of cysteine residues by using 2-
mercaptoethanol.   
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Figure 27. 2-mercaptoethanol breaking disulphide bonds (S-S) and preventing oxidation (loss of H+) 
of sulfhydryl groups (-SH).   
 
We know that 2-mercaptoethanol is embedding cardiac troponin I in a concentration 
of 15 mM, so it is possible that the resulting spectrum could be derived from the adsorption 
of 2-mercaptoethanol onto the surface of AgNPs instead of cardiac troponin I.  To confirm 
the suspicion of the adsorption of 2-mercaptoethanol onto the surface of AgNPs, the spectra 
of 2-mercaptoethanol was also performed as shown in Figure 28.  
 
 
Figure 28. Spectra of cardiac troponin I with AgNPs and 2-mercaptoethanol. 
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There is a perfect match between the spectra of 2-mercaptoethanol and the spectra 
of the presumably adsorbed cardiac troponin-I onto the surface of Ag NPs. Furthermore, 
these results are consistent with previous reports in the literature related with the 
chemisorption of 2-mercaptoethanol on metal structures [7]. The strongest Raman bands 
for the adsorbed 2-mercaptoethanol molecules are at 639 and 720 cm-1 assigned to the C-
S stretching, and about 1009 cm-1 due to out-of-phase C-C-O stretching. The presence of 
a weak band at 400 cm-1 is assigned to the C-C-O bending vibration. 
Despite the presence of such an obstacle, it was unintentionally found in this work 
that 2-mercaptoethanol had more affinity to AgNPs rather than AuNPs. This could have 
been influenced by differences in metal-S bonding or to the character and geometry of the 
sulphur-substrate bonding or even due to differences in size of the NPs [7, 8]. AgNPs were 
considerably larger than AuNPs (with an average diameter of 54.2 nm versus 14.4 nm for 
AuNPs). This result may be consistent with some reports indicating that larger sized NPs 
are shown to preserve disulphide bonds and for that reason are considered as the most 
appropriate substrates for ensuring the integrity of disulphide linkages [8].  
In order to continue with SERS measurements it was necessary to filtrate the 
protein, thus eliminating possible interferences resulting from the adsorption of 2-
mercaptoethanol on the surface of both metallic NPs. After filtration, the “pure” cardiac 
troponin I (initial concentration of 5×10-3 mM) was added again to the surface of both metallic 
NPs for further analysis. Figure 29 shows the resulting spectra of pure cardiac troponin I in 
different substrates.  
 
Figure 29. Spectra of the filtered cardiac troponin I on Au and Ag NPs. Peak evidence near 1533 
cm-1 when using AuNPs. 
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The spectra presented in Figure 29 do not show any evidence of 2-mercaptoethanol 
onto the surface of AgNPs, which indicates that the separation technique was apparently 
successful. There are no significant differences between the spectra of cardiac troponin I 
and the spectra of silver colloids. On the other hand, it is possible to identify a small band 
nearly 1533 cm-1 in the case of using AuNPs as substrates. This result aroused curiosity 
around the existence of such band and clearly showed that AuNPs may be a good candidate 
to be used as SERS substrate for the detection of this protein. However, it is important to 
note that the spectra of cardiac troponin I using AuNPs with 15 nm also showed bad 
resolution and poorly defined peaks, even with increased time scans. So, in order to improve 
the Raman signal of the protein and to get stronger band enhancements, the solution aimed 
for the increase of the size of the nanoparticle. It is known that when the nanoparticle 
diameter increases, the plasmon resonance shifts to higher wavelengths (getting closer to 
the laser’s irradiation source) leading to significant larger light-interaction cross-sections 
which greatly increases the scattering efficiency.  
Obviously, the next tests were performed using AuNPs with sizes around 35 and 96 
nm synthesized via seeding growth method. Figures 30 and 31 present the spectra of 
cardiac troponin I with different sized AuNPs as SERS platforms.  
 
 
Figure 30. Spectra of cardiac troponin I on the surface of AuNPs with sizes around 35 nm. 
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Figure 31. Spectra of cardiac troponin I on the surface of AuNPs with sizes around 96 nm. 
 
The spectra of the figures 30 and 31 show characteristic bands of peptides and 
including amide I, II and III bands [9]. The amide bands arise due to bond vibrations in the 
peptide units [10]. For instance, when two amino acids such as alanine and glycine are 
combined together, a molecule of water is eliminated to produce a dipeptide (Figure 32).  
 
Figure 32. Formation of an amide link between two amino acids by elimination of one molecule of 
water. 
 
H2O 
 
Amide  
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The linkage highlighted in blue in the structure of the dipeptide is known as a peptide 
or amide link whose vibrational frequencies, in this case, are being detected by SERS.   
The amide I band is typically found in the spectra region of 1700-1600 cm-1. The 
amide I band consists of C=O stretching vibrations with some contribution from N‐H bending 
[11, 12]. The amide II is usually found in the 1520 and 1540 cm-1 region and results from in-
plane N-H bending and from the C-N stretching vibration [13, 14]. Finally, the amide III band 
is found in the region of 1240-1310 cm-1 and results from stretching of C-N and N-H bending 
vibrations [14] 
In the SERS of cardiac troponin I as shown in figure 30 the amide bands appear at 
nearly 1642 cm-1 (amide I) and 1533 cm-1 (amide II). When the size of AuNPs increases 
from 35 to 96 nm, the most noticed bands are the amide II at 1533 cm-1 and the amide III at 
1298 cm-1, as shown in figure 31. It is worth noting that the amide II band is consistent with 
previous results and may be found in every spectra so far. The intensity of this band is 
strongly enhanced when the size of AuNPs is further increased.  
The amide II band was still identified without causing aggregation of particles with 
magnesium chloride (Mgcl2) as shown in figure 33. Mgcl2 was used throughout the work to 
cause aggregation of particles and to deliberately induce the formation of Hot-Spots in order 
to get greater signals by strong electromagnetic enhancements near metal junctions. 
 
 
Figure 33. Spectra of cardiac troponin I without the addition of magnesium chloride. 
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The detection limit of cardiac troponin I was also studied with different sample 
concentrations (initial concentrations of 1×10-2, 1×10-3, 1×10-4 mM) as shown in figure 34.  
 
Figure 34. Spectra of cardiac troponin I with different initial concentrations (1×10-2, 1×10-3, 1×10-4 
mM). 
 
This result suggests that the concentration of cardiac troponin I is indeed decreasing 
with more sample dilutions, which is in accordance with the decrease in the intensity of the 
spectra. If there was not any protein at all the spectra would have remained unaltered and 
with the same intensity because the only variable of the system is the concentration of the 
protein. Unfortunately, it was not possible to detect bands from aromatic side chain 
vibrations of amino acids such as phenylalanine, tryptophan or from SH/S- linkages between 
cysteine residues and the metal surface.  
Considering the hypothesis of the total removal of 2-mercaptoethanol during 
filtration, it is possible that, at alkaline pH, the protein rapidly undergoes reoxidation to form 
the original disulphide bonds, thus preventing the adsorption of these amino acids to the 
metal surface.  
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On the other hand, if there is still some amount of 2-mercaptoethanol it is also 
probable that 2-mercaptoethanol has formed some adducts with free cysteine residues, 
causing instability and interferences with protein-metal interactions. These factors could 
have contributed to inhibit some kind of interaction between cysteine residues and the metal 
surfaces. The non-identification of other amino acids in the spectrum could also be 
attributed to the distance of a certain moiety from the metal surface. If the polarizable part 
of some functional groups are distanced or not oriented towards the metal surface, it will be 
more difficult to be observed in the Raman spectra. That is why it is of great interest the 
functionalization of metal surfaces with biomolecules because they are capable to bind to 
specific targets, providing a specific Raman signal due to the interaction of the biomolecule 
with the target molecule.  
Since unmodified AuNPs were prepared through the classical citrate-reduction 
method and are loosely capped by negatively charged citrate ions they show high affinity to 
positively charged molecules and much less affinity to negatively charged ones. As a result, 
pH changes also may dictate interactions with some amino acids. The pH of ~ 35 and 96 
nm Au colloids was nearly 3.0. The low pH of AuNPs is due to the use of citric and ascorbic 
acids during the seeding-mediated growth method. When adding cardiac troponin I the pH 
increases to nearly 4. At this pH, the amino group in cysteine is positively charged and could 
interact with the negative charge on the surface of gold. However, in this work neither SH 
nor NH3+ of cysteine were bound with metal ions.  
Nevertheless, it was possible to identify amides with a simple intrinsic SERS 
configuration. The detection of amides could be attributed to the overall contribution from 
each and every amide summed, thus providing detectable signals with strong 
enhancements.   
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4. Conclusions and future work 
 
In this thesis it was given the first step towards the development of a novel SERS-
based aptasensor. SERS is a powerful microanalytical tool that provided information about 
the set of bonds between the different amino acids that compose cardiac troponin I. SERS 
spectra showed evidence of a possible detection of cardiac troponin I with a simple intrinsic 
SERS configuration by identifying characteristic bands of peptides and proteins such as 
amide bands. The presence of cardiac troponin I (even in such trace amounts) was indeed 
confirmed with the decrease of the detectable signal with more sample dilutions.  
AuNPs seem to be good candidates as SERS substrates for the detection of cardiac 
troponin I rather than AgNPs. As stated in this thesis, larger NPs are most suitable for 
biodetection purposes due to larger scattering cross-sections. The preferred adsorption of 
2-mercaptoethanol on the surface of AgNPs indicated that larger sizes may eventually 
foster metal-S interactions more easily.  
The presented work not only showed good insights for application of SERS in the 
area of clinical diagnosis, but also allowed to meet and deal with biodetection conundrums. 
In fact, much was learnt from circumstantial mistakes. For instance, the amount of cardiac 
troponin I (10 μg) was too low to make initial experiments, restraining any attempts of 
making other deeper spectroscopic studies. Next tests must be made with superior protein 
quantities. This will grant more access towards more environmental and structural data 
about cardiac troponin I, starting for example with the acquisition of the full spectrum of the 
native protein.  
The next cardiac troponin I to be supplied must be on its native form and without any 
kind of preservative stabilizers. Studies must be made by using cardiac troponin I as if it 
was directly removed from the blood. Research focus must be closer to these clinical details.  
Even if there are indicators that confirm the detection of cardiac troponin I with these SERS 
substrates, more work needs to be done to sustain previous statements, but this time by 
fusing an aptamer as a crosslink to the protein. Aptamers will play a major role in the specific 
detection of cardiac troponin I. They will make the technology absolutely unique and 
differentiated from competitors.  
The strategy of functionalization will be based on the introduction of a SH group at 
one end of the aptamer, leaving the other end directed to the outer-surface for specific 
interaction with cardiac troponin I. The process of functionalization is schematized in the 
following figure (Figure 35). 
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Figure 35. Preparation steps of the SERS-based aptasensor for the detection of cardiac troponin I. 
A thiol-modified aptamer is attached to the surface of the gold nanoparticles through gold-thiol bonds. 
In the presence of troponin I, the aptamer changes its conformation, binding with high affinity to 
cardiac troponin I.  
 
Once completed the stage of functionalization, technology validation will be 
achieved by showing that circulating levels of troponin are detected within the required 
specificity and sensitivity ranges. This step should be performed by attaching thiolated-
aptamers on metallic NPs with different shapes, sizes and compositions. If sensitivity needs 
to be lowered, there is a need for the pursuit of the ideal substrate. It is possible that the 
interaction between aptamers and metallic substrates may only function with a certain type 
of size or shape of NPs. There is an infinite “room” of possibilities to explore “at the bottom”! 
It is envisaged that the presented SERS-based aptasensor will have potential for the 
improvement of both sensitivity and specificity in future biosensing applications, making it 
widely conveyable to other relevant health challenges such as pathogen detection, cancer 
diagnosis, auto-immunity disorders… 
The potential of SERS for multiplexing will also be under study since it enables the 
measurement of multiple analytes in one single assay, another unique and truly innovative 
advantage in comparison with competitors. This feature not only tremendously reduces the 
costs with several biomarker testing orders, but also saves time for more straightforward 
clinical approaches. 
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The investment in a portable solution with multiplexing capability and an easy-to-use 
interface, opens the possibility of adopting a domiciliary device, with a vast array of potential 
future applications. For example, a multidisciplinary team of health professionals, equipped 
with a portable device, could provide a multitude of home services (e.g. diagnostics, 
screening tests, therapeutic control), or it could be rented to pharmacies or for private use, 
as appropriate.
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5.  Experimental 
5.1. Reagents  
 
Hydrogen tetrachloroaurate (III) trihydrate, ≥ 99.9% (HAuCl4.3H2O), sodium citrate 
tribasic dehydrate, ≥ 99.0% (Na3C6H5O7.2H2O) and silver nitrate, ≥ 99.8% (AgNO3) were 
purchased from Sigma-Aldrich, citric acid 1-hydrate, 99.5% (C6H8O7.H2O) was purchased 
from Panreac and L(+)-ascorbic acid, 99.7% (C6H8O6) was obtained from Riedel-de-Haёn. 
TRIS (Hydroxymethyl)-aminomethane, 99.8-100.1%  (NH2C(CH2OH)3) obtained from 
Pharmacia Biotech, sodium chloride, 99.5% (Nacl) provided from Panreac Química, calcium 
chloride dehydrate, 99.5% (Cacl2.2H2O) and  magnesium chloride hexahydrate, 99.8% 
(Mgcl2) purchased from Merck and cardiac troponin I, ≥98% supplied from AbD Serotec. 
Milli-Q water and distilled water were used throughout the work.  
5.2. Instrumentation  
5.2.1 UV-VIS  
 
UV-VIS spectrometry measures the degree at which light is absorbed by a medium 
at different wavelengths in the ultraviolet, visible and near infrared spectra [1]. This 
technique is used because Au and Ag NPs have strong plasmon resonance absorptions 
which are dependent on the size and shape of the particles [2]. Information on the average 
particle size can be obtained from the absorption maximum of the measured UV–VIS 
spectrum of the colloidal solution. The visible spectra of the colloids was recorded on a 
Jasco V-560 UV/VIS spectrophotometer using quartz cells.   
5.2.2 Zeta Potential  
 
Zeta potential analysis is a technique used to determine the surface charge of NPs 
in solution [3]. Almost all materials will spontaneously acquire a surface electrical charge 
when brought into contact with a liquid [4]. This charge may arise from some mechanisms 
such as ionization of surface groups, adsorption of charged species on the surface of the 
nanoparticle, among others. Since NPs possess a surface charge on their surface, they will 
attract a thin layer of ions of opposite charge, creating an electric double layer. The electric 
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potential at the boundary of the double layer is known as Zeta Potential of the particle with 
values typically ranging from +100 mV to -100 mV (Figure 36) [4, 5].  
 
Figure 36. Illustration of Zeta Potential. Adapted from [5] 
 
If all the particles in suspension have large positive or negative zeta potential then 
they will tend to repel each other and there will be no tendency for particles to come 
together. Therefore, the magnitude of the zeta potential is indicative of the stability of the 
colloidal system [6]. NPs with zeta potentials more positive than +25 mV or more negative 
than -25 mV are typically stable [7]. Colloids with lower values of zeta potential will 
eventually aggregate due to Van der Waals inter-particle attractions. Zeta Potential 
measurements were carried out on a ZetaSizer nano ZS Model Zen 3500 from Malvern 
Instruments using appropriate cells. 
5.2.3 Fourier Transform Infrared Spectroscopy (FTIR)  
 
FTIR is a technique based on the vibrations of the atoms in a molecule [8]. The infrared 
spectra is obtained by measuring the fraction of infrared radiation that is absorbed by the 
sample at a particular energy. The energy at which a peak appears in the spectrum 
corresponds to the frequency of a vibration of a part of a sample molecule.  
FTIR spectra were recorded using a FT Mattson 7000 Spectrometer with resolution of 4 cm-
1 after 256 scans. A few drops of colloid solutions were added to 200 mg of potassium 
bromide (KBr) and left to dry in an oven at 75ºC.  The resulting solid residue was used to 
prepare pellets for FTIR analysis. 
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5.2.4 (Scanning) Transmission Electron Microscopy (TEM/STEM) 
 
TEM/STEM can yield information such as particle size, size distribution and 
morphology of the NPs. The size of the NPs was directly observed and measured using a 
Hitachi SU-70 at an accelerating voltage of 15 kV (STEM) and a Hitachi H-9000 microscope 
operated at an accelerating voltage of 300 kV (TEM). STEM and TEM samples were 
prepared by placing a drop of the diluted colloids at room temperature on carbon-coated 
copper grids. Size distribution of the NPs was determined on the basis of the obtained 
micrographs with the use of the Image J program. The calculated sizes are expressed as 
the diameter of a sphere that has the same projected area as the projected image of the 
particle.  
5.2.5 Surface-enhanced Raman Scattering (SERS) 
 
Raman spectra were recorded using a Bruker RFS100/S FT- Raman spectrometer 
(Nd:YAG laser, 1064 nm excitation), at a power of 350 mV, with 500/1000 scans at a 
resolution of 2 cm−1.  
5.2.6 Amicon Ultra Centrifugal filters  
 
Amicon Ultra 0.5 ml centrifugal filters, purchased from Sigma Aldrich, with a 
Molecular Weight Cut-Off (MWCO) of 3 kDa were used to remove 2-mercaptoethanol from 
cardiac troponin I.  
 
5.3. Prior requirements for metallic nanoparticle synthesis  
 
Firstly, all glassware was thoroughly washed prior to use with aquaregia solution 
(HCl: HNO3 = 3:1) and rinsed with deionized water. The synthesis of metallic NPs was 
always carried out inside a well-ventilated Hotte.  
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5.4. Synthesis of Au and Ag NPs  
 
AuNPs were synthesized by the reduction of hydrogen tetrachloroaurate (III) 
trihydrate (HAuCl4.3H2O) with sodium citrate dehydrate solution (Na3C6H5O7.2H2O). 
 A 50 ml gold solution (1 mM) was prepared in a 2-neck round-bottom flask with the center 
neck attached to a reflux condenser. The flask was set in a hot plate with a magnetic stirrer 
to provide vigorous stirring and a thermometer was inserted to accurately measure the 
temperature of the solution. (Figure 37).  
 
 
Figure 37. Metallic nanoparticle synthesis experimental setup. 
  
A reflux condenser is used to cool down vapors arising from the solvent as they flow 
through the tube, leading to the condensation of the solvent. Since the condensed solvent 
falls back into the reaction vessel, any significant loss of volume of the solvent was 
prevented during the heating process. 
When the solution almost reached its boiling point (90-100 ºC), 5 ml of sodium citrate 
(38.8 mM) were added rapidly in continuous mode to the 50 ml of HAuCl4.3H2O solution. 
The solution was kept in reflux for 1 hour. A color change was observed within the first 
minutes from pale yellow, through colorless to black and finally to a wine-red colored 
solution, indicating the formation of AuNPs. After 1 hour of heating the hot plate was 
switched off and the solution was left for cooling at room temperature with continuous 
agitation.   
 
AgNPs were prepared by using a chemical reduction method. Distilled water was 
used to prepare all reacting solutions. For this synthesis, a 2-neck round-bottom flask 
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containing a solution of 50 ml of the aqueous AgNO3 (1×10-3 M) was placed on the top of a 
heater plate and heated up to boiling temperature. As soon as the solution commenced to 
boil, 1 ml of sodium citrate solution (1%) was added drop by drop to the AgNO3 solution. 
Vigorous stirring and boiling of the solution were kept during the whole process. The colour 
of the solution slowly turned into greyish yellow, indicating the reduction of the Ag+ ions and 
so the formation of AgNPs. The reaction solution was maintained in reflux with vigorous 
mechanical stirring for 45 minutes and was later left to cool down to room temperature with 
continuous stirring.  
5.5. Seed-mediated growth of AuNPs 
 
Seed particle solutions were prepared according to the standard citrate reduction 
method. Firstly, 1.25 ml of a 10 mM HAuCl4.3H2O solution (0.2% w/v) in 50 ml of deionized 
water was heated to boiling. At the same time, a solution of sodium citrate (1% w/v) 
containing citric acid (0.05% w/v) was prepared in 20 ml of deionized water. Then 2 ml of 
the sodium citrate containing citric acid solution were added quickly under vigorous stirring. 
The solution was kept in boiling for 5 minutes and was then allowed to cool down for 30 
minutes. The colour of the mixed solution changed to wine red in several minutes, indicating 
the formation of AuNPs.  
For the first growth step, 3 ml of the prior resulting seed solution were diluted to 20 
ml and placed into a 3-neck bottom flask. Another two solutions were additionally prepared: 
one solution was prepared by diluting 2.25 ml of HAuCl4.3H2O (10 mM) to 25 ml of deionized 
water and the other one was prepared by diluting a mixture of 1.25 ml of ascorbic acid 
solution (1%) and 0.625 ml of sodium citrate (1%) again to 25 ml. A 10 ml aliquot of the 
aforementioned solution containing HAuCl4.3H2O (0.9 mM) and 10 ml of the aforementioned 
reducing solution containing sodium citrate and ascorbic acid were added separately to the 
3-neck bottom flask at room temperature through Teflon tubes via a peristaltic pump under 
vigorous stirring over a time of about 42 minutes. After the addition was complete the 
mixture was brought to boiling for about 30 minutes.  
For the second growth step, 4.5 ml of the resulting seed solution were diluted in 20 ml and 
placed again into a new and washed 3-neck bottom flask. Similarly, a 10 ml aliquot of the 
solution containing HAuCl4.3H2O (0.9 mM) and 10 ml of the solution containing sodium 
citrate (1%) and ascorbic acid (1%) were added separately to the 3-neck bottom flask. The 
mixture was then brought to boiling for about 30 minutes and allowed to cool down.  
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5.6. Filtration of cardiac troponin I (Removal of 2-mercaptoethanol)   
 
100 μl of a buffer solution were added to the centrifugal filter containing 100 μl of 
protein. The solution was then put to centrifuge. Centrifugations were carried out at 12.000 
g for 20 minutes. Cardiac troponin I was diluted until a final concentration of 5×10-3mM 
(Figure 38).  
              
Figure 38. Illustration of the filtration of cardiac troponin I. 
5.7. Buffer solution preparation  
 
The buffer solution (pH=9.2) used for stabilization and preservation of the filtered 
cardiac troponin I was composed by 500 mM of sodium chloride (Nacl), 40 mM of TRIS 
(C4H11NO3), 4mM of magnesium chloride (Mgcl2) and 4 mM of calcium chloride (Cacl2).   
 
5.8. Preparation of samples for SERS assays 
 
Samples for SERS measurements were prepared by adding 10 µl (5×10-3 mM) of 
human cardiac troponin I to 990 µl of colloids. Magnesium chloride (Mgcl2) was added to 
the colloid to induce aggregation. 
Chapter 5 – Experimental 
 
76 
 
5.9. References 
 
[1] Owen, T., Fundamentals of UV-Vis spectroscopy, 1996. 
[2] Stiufiuc, R., lacovita, C., Lucaciu, C., Stiufiuc, G., et al., "SERS-active silver colloids 
prepared by reduction of silver nitrate with short-chain polyethylene glycol", 
Nanoscale Research Letters, vol. 8, pp. 1-5, 2013. 
[3] Lungu, M., Enescu, E., Grigore, F., Buruntia, N., et al., "Chemical preparation and 
properties of some high concentrated colloidal silver solutions for antimicrobial 
applications", Revue Roumaine de Chimie, vol. 57, pp. 849-855, 2012. 
[4] Erickson, D., Li, D., and Werner, C., "An Improved Method of Determining the zeta-
Potential and Surface Conductance", Journal Colloid and Interface Science, vol. 
232, pp. 186-197, 2000. 
[5] http://www.silver-colloids.com/Tutorials/Intro/pcs17.html (22-07-2014). 
[6] Zhang, Y., Yang, M., Portney, N. G., Cui, D., et al., "Zeta potential: a surface 
electrical characteristic to probe the interaction of nanoparticles with normal and 
cancer human breast epithelial cells", Biomedical Microdevices, vol. 10, pp. 321-8, 
2008. 
[7] Luque, R. and Varma, R. S., Sustainable preparation of metal nanoparticles, 2013. 
[8] Stuart, B., Infrared Fundamentals and Applications, 2004. 
 
